학술논문
Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease.
Document Type
Academic Journal
Author
Ally M; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Psychology University of Arizona Tucson Arizona USA.; Sugarman MA; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurology Medical University of South Carolina Charleston South Carolina USA.; Zetterberg H; Department of Neurodegenerative Disease UCL Institute of Neurology London UK.; UK Dementia Research Institute at UCL, UCL Institute of Neurology University College London London UK.; Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg Gothenburg Sweden.; Blennow K; Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg Gothenburg Sweden.; Ashton NJ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg Gothenburg Sweden.; Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology, and Neuroscience King's College London London UK.; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation London UK.; Centre for Age-Related Medicine Stavanger University Hospital Stavanger Norway.; Karikari TK; Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg Gothenburg Sweden.; Department of Psychiatry University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA.; Aparicio HJ; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Frank B; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; US Department of Veterans Affairs VA Boston Healthcare System Jamaica Plain Massachusetts USA.; Tripodis Y; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Biostatistics Boston University School of Public Health Boston Massachusetts USA.; Martin B; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Biostatistics and Epidemiology Data Analytics Center Boston University School of Public Health Boston Massachusetts USA.; Palmisano JN; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Biostatistics and Epidemiology Data Analytics Center Boston University School of Public Health Boston Massachusetts USA.; Steinberg EG; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Simkin I; Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Farrer LA; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Biostatistics Boston University School of Public Health Boston Massachusetts USA.; Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; The Framingham Heart Study Framingham Massachusetts USA.; Department of Epidemiology Boston University School of Public Health Boston Massachusetts USA.; Department of Ophthalmology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Jun GR; Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Turk KW; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; US Department of Veterans Affairs VA Boston Healthcare System Jamaica Plain Massachusetts USA.; Budson AE; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; US Department of Veterans Affairs VA Boston Healthcare System Jamaica Plain Massachusetts USA.; O'Connor MK; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neuropsychology Edith Nourse Rogers Memorial Veterans Hospital Bedford Massachusetts USA.; Au R; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; The Framingham Heart Study Framingham Massachusetts USA.; Department of Epidemiology Boston University School of Public Health Boston Massachusetts USA.; Department of Neurology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Anatomy and Neurobiology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Goldstein LE; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Biostatistics and Epidemiology Data Analytics Center Boston University School of Public Health Boston Massachusetts USA.; Department of Ophthalmology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Biomedical, Electrical, and Computer Engineering Boston University College of Engineering Boston Massachusetts USA.; Kowall NW; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; US Department of Veterans Affairs VA Boston Healthcare System Jamaica Plain Massachusetts USA.; Department of Pathology and Laboratory Medicine Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Killiany R; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Anatomy and Neurobiology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Center for Biomedical Imaging Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Stern RA; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Anatomy and Neurobiology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurosurgery Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Stein TD; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; US Department of Veterans Affairs VA Boston Healthcare System Jamaica Plain Massachusetts USA.; Department of Pathology and Laboratory Medicine Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; US Department of Veterans Affairs VA Bedford Healthcare System Bedford Massachusetts USA.; McKee AC; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; US Department of Veterans Affairs VA Boston Healthcare System Jamaica Plain Massachusetts USA.; Department of Pathology and Laboratory Medicine Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; US Department of Veterans Affairs VA Bedford Healthcare System Bedford Massachusetts USA.; Qiu WQ; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Psychiatry Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Pharmacology and Experimental Therapeutics Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Mez J; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Alosco ML; Boston University Alzheimer's Disease Research Center and CTE Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.; Department of Neurology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA.
Source
Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101654604 Publication Model: eCollection Cited Medium: Print ISSN: 2352-8729 (Print) Linking ISSN: 23528729 NLM ISO Abbreviation: Alzheimers Dement (Amst) Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2352-8729
Abstract
Introduction: This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p-tau) 181+231 .
Methods: Plasma samples were analyzed using Simoa platform for 567 participants spanning the AD continuum. Cognitive diagnosis, neuropsychological testing, and dementia severity were examined for cross-sectional and longitudinal outcomes.
Results: Plasma GFAP discriminated AD dementia from normal cognition (adjusted mean difference = 0.90 standard deviation [SD]) and mild cognitive impairment (adjusted mean difference = 0.72 SD), and demonstrated superior discrimination compared to alternative plasma biomarkers. Higher GFAP was associated with worse dementia severity and worse performance on 11 of 12 neuropsychological tests. Longitudinally, GFAP predicted decline in memory, but did not predict conversion to mild cognitive impairment or dementia.
Discussion: Plasma GFAP was associated with clinical outcomes related to suspected AD and could be of assistance in a plasma biomarker panel to detect in vivo AD.
Competing Interests: The authors MA, MAS, TKK, HJA, BF, YT, BM, JNP, EGS, IS, LAF, GRJ, KWT, AEB, MKO, LEG, NWK, RK, TDS, ACM, WQ, and JM have no competing interests to declare. HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, on advisory boards, or on data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. NJA has given lectures in symposia sponsored by Eli‐Lily. AEB has served as a consultant or on advisory boards for Eli Lilly and Roche Pharmaceuticals and has received grant monies from Cumulus Neuroscience, VoxNeuro, Bristol Myers Squibb, and Cyclerion. He receives publishing royalties from Elsevier and Oxford University Press. RA serves on the scientific advisory board of Signant Health, as consultant to Biogen, and has given a lecture in a symposium sponsored by Eisai. RAS has served as a consultant to Biogen and Lundbeck. He receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. MLA has received honorarium from the Michael J. Fox Foundation for services unrelated to this study. He receives royalties from Oxford University Press.
(© 2023 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.)
Methods: Plasma samples were analyzed using Simoa platform for 567 participants spanning the AD continuum. Cognitive diagnosis, neuropsychological testing, and dementia severity were examined for cross-sectional and longitudinal outcomes.
Results: Plasma GFAP discriminated AD dementia from normal cognition (adjusted mean difference = 0.90 standard deviation [SD]) and mild cognitive impairment (adjusted mean difference = 0.72 SD), and demonstrated superior discrimination compared to alternative plasma biomarkers. Higher GFAP was associated with worse dementia severity and worse performance on 11 of 12 neuropsychological tests. Longitudinally, GFAP predicted decline in memory, but did not predict conversion to mild cognitive impairment or dementia.
Discussion: Plasma GFAP was associated with clinical outcomes related to suspected AD and could be of assistance in a plasma biomarker panel to detect in vivo AD.
Competing Interests: The authors MA, MAS, TKK, HJA, BF, YT, BM, JNP, EGS, IS, LAF, GRJ, KWT, AEB, MKO, LEG, NWK, RK, TDS, ACM, WQ, and JM have no competing interests to declare. HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, on advisory boards, or on data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. NJA has given lectures in symposia sponsored by Eli‐Lily. AEB has served as a consultant or on advisory boards for Eli Lilly and Roche Pharmaceuticals and has received grant monies from Cumulus Neuroscience, VoxNeuro, Bristol Myers Squibb, and Cyclerion. He receives publishing royalties from Elsevier and Oxford University Press. RA serves on the scientific advisory board of Signant Health, as consultant to Biogen, and has given a lecture in a symposium sponsored by Eisai. RAS has served as a consultant to Biogen and Lundbeck. He receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. MLA has received honorarium from the Michael J. Fox Foundation for services unrelated to this study. He receives royalties from Oxford University Press.
(© 2023 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.)